Can chronic inflammatory signaling disrupt insulin pathways in muscle, liver, and brain?

Chronic low-grade inflammatory signaling is a credible contributor to insulin resistance, particularly in skeletal muscle, with likely relevance to whole-body glucose control. The broader extension to liver and brain is biologically coherent but less directly demonstrated in tissue-specific human causal studies.

Clinical and metabolic evidence

• In skeletal muscle, inflammatory signaling can impair insulin-stimulated glucose uptake. Because muscle is a major site of postprandial glucose disposal, reduced muscle insulin action has a well-established capacity to worsen systemic glycemic control.
• Hepatic insulin-pathway impairment would be expected to worsen dysglycemia by weakening insulin’s restraint of hepatic glucose production. The inflammation-to-hepatic-insulin-resistance link is mechanistically supported, although direct tissue-resolved human evidence is less definitive.
• In the brain, inflammatory/stress signaling is associated in animal aging models and Alzheimer brain tissue with impaired insulin responsiveness. Central insulin resistance is also associated with reduced cortical glucose use and mitochondrial oxidative-phosphorylation abnormalities, but it is not established as a sole cause of neuronal bioenergetic dysfunction.

Mechanistic basis

• TNF-α–linked inflammatory activity can activate JNK and IKKβ.
• JNK activation can increase inhibitory serine phosphorylation of insulin-receptor substrate-1 (IRS-1), weakening insulin-stimulated IRS-1–PI3K–AKT signaling.
• This pathway provides a coherent mechanism connecting chronic inflammation to reduced insulin action in insulin-responsive tissues.

Interpretation and clinical implications

• Cytokine effects are context dependent: IL-6 is not uniformly metabolically harmful, and anti-inflammatory interventions have not provided a simple confirmation of causality. IL-1 blockade has produced inconsistent insulin-sensitivity effects, while TNF inhibition has not consistently improved metabolic measures.
• Brain glucose entry is predominantly mediated by insulin-independent GLUT1 and GLUT3 transporters; therefore, impaired neuronal insulin signaling does not automatically imply globally impaired cerebral glucose uptake.

Bottom line

• Chronic inflammation is well supported as a disruptor of muscle insulin signaling and a contributor to systemic dysglycemia. Similar liver and brain effects, including possible consequences for neuronal energy metabolism, remain plausible rather than conclusively established in humans.